CYDY Stock Overview
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CytoDyn Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$0.42 |
| 52 Week Low | US$0.13 |
| Beta | 0.19 |
| 1 Month Change | -11.61% |
| 3 Month Change | -8.39% |
| 1 Year Change | -47.60% |
| 3 Year Change | -94.90% |
| 5 Year Change | -64.64% |
| Change since IPO | -77.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYDY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 1.0% | 1.2% |
| 1Y | -47.6% | 0.7% | 24.9% |
Return vs Industry: CYDY underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CYDY underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| CYDY volatility | |
|---|---|
| CYDY Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYDY's share price has been volatile over the past 3 months.
Volatility Over Time: CYDY's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 12 | Jay Lalezari | www.cytodyn.com |
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.
CytoDyn Inc. Fundamentals Summary
| CYDY fundamental statistics | |
|---|---|
| Market cap | US$148.93m |
| Earnings (TTM) | -US$53.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs CYDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYDY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$53.17m |
| Earnings | -US$53.17m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -25.3% |
How did CYDY perform over the long term?
See historical performance and comparison